Should I choose preimplantation genetic testing for aneuploidy (PGT-A) as part of my IVF lab plan?

PGT-A is a laboratory test that provides information about whole chromosomes (large pieces of DNA) in individual embryos. Abnormal chromosome copy numbers (there should be two and only two copies of each of the 23 chromosomes in a human cell) are a major contributor to impaired reproductive capability and the incidence of abnormal chromosome content is strongly related to age. The goal of PGT-A is to “screen out” embryos with chromosome problems. In practice, current clinical research supports the use of this technology (especially in patients of advanced reproductive age) however it is important to understand testing limitations. From a scientific perspective the testing methods are extremely complex and validity and reproducibility capabilities are continuously evolving. For example, our field’s current best estimates regarding false positive or false negative results is somewhere around 2-4%. Ultimately the use of PGT-A by patients is an individual choice made after careful consideration, ranking values such as cost, past reproductive experiences (going through a miscarriage), general reproductive viewpoints and long term family building goals.